Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Knopp Biosciences Completes Enrollment In Phase 2 Trial Of Oral Dexpramipexole In Eosinophilic Asthma is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma - Markets Insider
PITTSBURGH, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Knopp Biosciences LLC today announced the completion of enrollment in a Phase 2 trial of the oral small-molecule dexpramipexole in patients with ... Read More
Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021 - Business Wire
Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small ... Read More
Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma - Yahoo Finance
PITTSBURGH, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Knopp Biosciences LLC today announced the completion of enrollment in a Phase 2 trial of the oral small-molecule dexpramipexole in patients with ... Read More
Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma - Business Wire
EXHALE was a randomized, double-blind, Phase 2 trial assessing the efficacy and safety of 75 mg/day, 150 mg/day, and 300 mg/day of oral dexpramipexole vs. placebo in reducing blood eosinophil ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus